

Plants of Tomorrow


HC70A & SAS70A Spring 2017 Genetic Engineering in Medicine, Agriculture, and Law

Professors Bob Goldberg & John Harada, Lecture 6

Twenty-First Century Genetic Engineering
Applications








Themes

- 1. What is a GMO?
- 2. What Are the Three Procedures to Engineer Cells?
- 3. How Do Classical Breeding, Foreign Gene Insertion, and Editing Differ?
- 4. What is Marker Assisted Breeding and How Can It Speed Up Crop Improvement?
- 5. What Are Industrial Applications of Genetic Engineering?
- 6. How Can Genetic Engineering Be Used To Eliminate or Reduce Mosquito Populations?
- 7. What is the CRISPR-Cas Bacterial Immunity System?
- 8. What Are the Individual Components of the CRISPR-Cas Immunity System?
- 9. How Can CRISPER-Cas9 be Used For Gene Editing?
- 10. What is Gene Drive and How Can it Be Used To Fight Malaria?
- 11. What Are the Ethical and Regulatory Concerns of Using Gene Drive Systems?
- 12. What Are Other Applications of CRISPR-Cas9 Editing?
- 13. What Are the Ethical Concerns For Editing the Human Genome in Somatic and Germ Cells




Genetic Engineering is a **TECHNIQUE!**

- 1. Classical Breeding By Selective Mating (Thousands of Years)
- 2. Insertion of New Genes Into An Organism's Chromosomes (50 Years)
- 3. Editing Existing Genes Like A "Word Program" (1-2 Years)

Breeding or DNA Manipulation - They
Are the <u>SAME</u>
&

Called Gene Manipulation WHAT IS A GMO???



Genetic Engineering is a **TECHNIQUE!**


- 1. Classical Breeding By Selective Mating (Thousands of Years)
- 2. Insertion of New Genes Into An Organism's Chromosomes (50 Years)
- 3. Editing Existing Genes Like A "Word Program" (1-2 Years)

Breeding or DNA Manipulation - They Are the <u>SAME</u>

å

Called Gene Manipulation WHAT IS A GMO???

Engineering Corn From the Wild Grass Teosinte



Note: Architecture and Fruit (cob) Size

Only Five Genes Cause These Plants to Differ & We Now Know What They Are

Breeding Uses Natural Genetic Variability of Genes As Raw Material - Variability Generated by Mutations







Nikolai Vavilov 1887-1943

Mutations in a Gene That Change Its Chemical Sequence & Slightly Alters Its Function (e.g., fruit size, color)



Plants of Tomorrow







The Problem With Breeding the "Old Fashioned Way"

Cannot Predict Results!
Takes Many Generations - Slow!







Breeding the 21st Century Way Can Predict Results! Identifying Crop Diversity Genes/Alleles



The 3,000 rice genomes project

The 3,000 rice genomes project 1,2,3*+











Using DNA Fingerprints to Identify Traits in Breeding Program - Marker Assisted Breeding



Advantages

- Speed Up Breeding Program
- More Predictable Breeding Program




Genetic Engineering is a **TECHNIQUE!**


- 1. Classical Breeding By Selective Mating (Thousands of Years)
- 2. Insertion of New Genes Into An Organism's Chromosomes (50 Years)
- 3. Editing Existing Genes Like A "Word Program" (1-2 Years)

Breeding or DNA Manipulation - They
Are the <u>SAME</u>

Called Gene Manipulation WHAT IS A GMO???







One of the Most Important Applications of Genetic Engineering Technology Has Been To Manufacture Drugs & Vaccines to Treat Human and Animal Diseases














Created a Multibillion Dollar Biotechnology Industry, Was Responsible For the Acceptance of Recombinant DNA Technology in the 1970s,& Lead to Pioneering Decisions in Patent Law






Engineering an Animal Cell to Make a Human Protein (e.g., Factor VIII)



Recall:
Extraordinary
Measures,
Pompe's Disease
&
α-Glucosidase

Enzyme





Sheep ovum

Sheep ovum

DNA is injected into promudeus

Holding pipete

Implant into foater mother

Popetral of YFG is restricted to mammary tissue

Obtain milk from transgenic animals

PFG product is secreted into milk

Animals Can Also be Used as Factories to Produce Large Amounts of Human Proteins

Advantages of Molecular Pharming

- 1. Many human proteins need to be modified after translation to be active. Only eukaryotic cells can do this.
- 2. Bacteria need big fermentors + elaborate protein purification schemes-Farm animals can be used for this purpose w/o special processing/machinery.
- 3. Proteins stable, can be made in large amounts, and purified easily



Protein!

February 7, 2009

F.D.A. Approves Drug From Gene-Altered Goats

Examined Data From Seven Generations of Genetically Engineered Goats

New Drug From Genetically Engineered Goat

rotein antithrombin is

ources: GTC Biotherapeutics

nserted into a short

trand of goat DNA.


FDA OKs ATryn, 1st Drug Made in Milk of a Genetically Engineered Animal

By Miranda Hitti WebMD Health News

Feb. 6, 2009 -- The FDA today approved ATryn, the first drug made in genetically engineered animals.

Issues
Food Supply?
Containment?
Animal Health?
Effective Drug?





IMPLANTING THE DNA
The modified DNA is
injected into the nucleus
of a fertilized goat egg,
which is then implanted
into a female.


TESTING THE OFFSPRING
Kids born from the modified
eggs are tested for the
presence of antithrombin in
their milk. Promising kids
their milk. Promising kids
are bred normally to create
a herd of modified goats.

EXTRACTING THE PROTEIN Milk from the herd is filtered and purified. Annually, each goat can produce as much antithrombin as 90,000 human blood donations.





Genetically Engineered Drug-Producing Mammals Can Also Be Cloned



Somatic Cells
Can Also Be
Genetically
Engineered and
Then Inserted
Into Egg

And Don't Forget Plants!

First plant-made biologic approved



Drug Administration in May approved Elelyso (taliglucerase alfa), an enzyme produced in genetically engineered carrot cells, for treating type 1 Gaucher's disease. This is the first plant-made

The US Food and

Carrot cell


by the regulators, and for Israeli company Protalix BioTherapeutics of Carmiel, it is the first product made in their ProCellEx protein expression system to reach the market. The plant cell platform produces recombinant proteins with a glycan and amino acid structure similar to naturally produced human counterparts. Some 10,000 patients worldwide have Gaucher's, a rare genetic disorder in which individuals fail to produce the enzyme glucocrebrosidase.


Drug-making plant blooms

Approval of a 'biologic' manufactured in plant cells may pave the way for similar products.

PLANTS IN THE PIPELINE Manufacturers have begun or completed phase II clinical trials on a handful of biologics made in plants, and hope to follow Elelyso to market. Condition Company Platform Hepatitis C Locteron **Biolex Therapeutics** Duckweed (interferon-α) H5N1 vaccine Influenza Medicago Tobacco VEN100 Antibiotic-associated diarrhoea Ventria Bioscience Rice CaroRx Dental caries Planet Biotechnology Tobacco

Elelyso® Made in Engineered Carrot Cells
To Treat Gaucher's Disease - A Lysosomal
Storage Disease That Prevents Molecules
From Being Degraded and Disposed of Properly
in Cells - 100x Prevalence in Ashkenazi Jews.
Gene on Chromosome 1, and Encodes a
Glucocerebrosidase.
Advantages of Plants?





Cloning: Ethical Issues and Future Consequences







Using Genetic Engineering to Make Vaccines







Using Genetic Engineering To Make Vaccines



Clone Pathogenic
Antigen Gene in
E. Coli or
Other Host (e.g.,
Yeast, Virus)
And Synthesize
Large Amounts of
Antigen

Synthetic Biology Can Be Used to Rapidly Synthesize Vaccines

VACCINES

Synthetic Generation of Influenza Vaccine Viruses for Rapid Response to Pandemics

Synthetic Biologists Engineer A Custom Flu Vaccine In A Week

A synthetic biology method proves its chops.

Synthetic Biology Could Speed Flu Vaccine Production


Advanced genetic engineering is already changing vaccine development and could make inroads into other branches of medicine.



Vaccines Work With Body Immune System

HOW A VACCINE WORKS


Creating Immunity



A weakened form of a disease antigen – that may be dead or living – is injected into the body.

The body reacts to the antigen by creating antibodies to attack it.

If the certain antigen ever enters the body again, the body's immune system antibodies will be able to fight against it.





Vaccines Work!!!



TABLE 12.1 Annual cases in Canada from various diseases before and after the introduction of vaccines against the causative agents of the diseases

Disease	Annual no. of cases before vaccine was introduced	No. of cases in 2002
Polio	20,000	0
Diphtheria	9,000	0
Rubella	69,000	16
Mumps	52,000	197
Haemophilus influenzae type b infection	2,000	48
Whooping cough	25,000	2,557
Measles	300,000	7






DNA Fingerprinting



Cloning: Ethical Issues







California Vaccination Requirements

GUIDE TO IMMUNIZATIONS REQUIRED FOR SCHOOL ENTRY

Grades K-12



INSTRUCTIONS

Use this guide as a quick reference to help you determine whether children seeking admission to your school meet California's school immunization requirements. For the actual laws, see Health and Safety Code, Division 105, Part 2, Chapter 1, Sections 120325-120380; California Code of Regulations, Title 17, Division 1, Chapter 4, Subchapter 8, Sections 6000-6075. If you have any questions, call the Immunization Coordinator at your local health department.

IMMUNIZATION REQUIREMENTS

To enter into public and private elementary and secondary schools (grades kindergarten through 12, including transitional kindergarten), children under age 18 years must have immunizations.

VACCINE	REQUIRED DOSES	
Polio	4 doses at any age, but 3 doses meet requirement for ages 4–6 years if at least one was given on or after the 4th birthday!; 3 doses meet requirement for ages 7–17 years if at least one was given on or after the 2th birthday.	
Diphtheria, Tetanus, and Pertussis	Age 6 years and under: DTP, DTaP or any combination of DTP or DTaP with DT (diphtheria and tetanus) 5 doses at any age, but 4 doses meet requirements for ages 4–6 years if at least one was on or after the 4 th birthday.¹	
	Age 7 years and older: Tdap, Td, or DTP, DTaP or any combination of these 4 doses at any age, but3 doses meet requirement for ages 7–17 years if at least one was on or after the 2 nd birthday.¹ If last dose was given before the 2 nd birthday, one more (Tdap) dose is required.	
Measles, Mumps, Rubella (MMR)	Age 4-6 years (kindergarten and above): 2 doses² both on or after 1st birthday.¹	
	7 th grade: 2 doses ² both on or after 1 st birthday. ¹	
	Age 7-17 years and not entering or advancing into 7th grade: 1 dose on or after 1st birthday.1	
Hepatitis B ³	Age 4-6 years (kindergarten and above): 3 doses.	
Varicella	1 dose ^{4, 6}	
Tdap Booster (Tetanus, reduced diphtheria, and pertussis)	7th grade: 1 dose on or after 7th birthday. 5,7	

STATE NEWS



California Passes a 'No Exemption' Vaccination Policy for School Children. California Governor Jerry Brown signed S.B. 277 into law. The law will ban the use of personal or religious beliefs as grounds for exemption from vaccination, mandating that all children must be vaccinated by the beginning of school. California joins two other states, Mississippi and West Virginia, which do not have any exemptions for vaccination – though

students in all three states may still opt out if a doctor says they should not get vaccinated for a medical reason. The law's passage comes following a deadly outbreak of measles in Disneyland.










Industrial & Food Products Made With Genetic Engineering








Bacteria & Other Microbes Are the Source Of Many Different Products



Specific Proteins and/or Metabolic Pathways Can Be Improved and/or Manipulated By Recombinant DNA!







Bacteria Can Be Engineered To Degrade Biomass Waste-Containing Cellulose (e.g., paper)




Figure 13.27 Enzymatic biodegradation of cellulose. Cellulose hydrolysis begins with the cleavage of β -1,4-linkages within the accessible amorphous regions of the cellulose chains by endoglucanase(s). This reaction is followed by the removal of oligosaccharides from the reducing ends of the partially cleaved cellulose chains by exoglucanase(s) and cellolobidydrolase(s). The degradation of cellulose is completed when the cellobiose and cellotriose are converted to glucose by β -glucosidase.

Agriculture, Timber Processing, Human Activities: e.g., Plants Left Over From Harvests, Animal Manure With Grasses, Municipal Water Paper, Cotton Leftovers, Hay, Etc.

Engineering E. coli To Synthesize Indigo- The Major Blue Dye For Jeans & Other Clothes & Uses







Figure 12.8 Indigo biosynthesis from tryptophan in genetically engineered E. coli. Tryptophanase is an E. coli enzyme. In pathway A, the naphthalene dioxygenase is derived from the NAH plasmid; in pathway B, the xylene oxidase is from the TOL plasmid. E. coli transformants that synthesize indigo contain either pathway A or B but not both pathways.

\$200M/Year Industry
Indigo Previously Obtained From Plants!

Bacteria Can Be Engineered To Degrade Several Different "Toxic" Compounds OCT plasmid NAH plasmid Mating XYL plasmid **Pseudomonas** CAM/OCT NAH plasmid CAM/OCT plasmid - XYL plasmid A Landmark Decision- Diamond vs. Chakrabarty Figure 13.5 Schematic representation of the development of a bacterial strain that can degrade camphor, octane, xylene, and naphthalene. Strain A, which contains a CAM (camphor-degrading) plasmid, is mated with strain B, which carries an OCT (octane-degrading) plasmid. Following plasmid transfer and homologous recombination between the two plasmids, strain E carries a CAM and OCT biodegradative fusion plasmid. Strain C, which contains a YXL (xylene-degrading) plasmid, is mated with strain D, which contains a NAH (naphthalene-degrading) plasmid, is orm strain E, which carries both of these plasmids. Finally, strains E and F are mated to yield strain C, which carries the CAM/OCT fusion plasmid, the XYL plasmid, and the NAH plasmid. Chakrabarty US Patent 4,259,444 1981 Genetically Engineered Microorganisms Are "Inventions" Life Can Be Patented!







Chymosin (Rennin)
Acts On Milk
Proteins To
Coagulate Milk →
Cheese



Is Cheese A GMO?



Chymosin In Cheese Making

- 1. ~80-90% of Cheeses Are Made With Recombinant Chymosin (a Protease)
- 2. Approved For Use In Cheese Making By FDA 1992
- 3. Not Different From Non-Recombinant Chymosin∴ GRAS- Generally Regarded As Safe & No
 Labeling Needed Because Not An Additive &
 Not Different From Non-Recombinant Chymosin!!


Is Cheese Made Using Recombinant Chymosin a GMO?

Industry Adds Claim That Recombinant Chymosin is "Kosher" & "Vegetarian"




Why No Fuss?





Genetic Engineering Can Be Used To Make Better/More Effective Antibiotics




By Modifying
Pathways
Leading to
Antibiotics
In Bacterial Cells.
But Need To Know
Genes/Proteins in
Pathway
&
By Finding Their
Targets
In
Pathogens As Well







Using Genetic Engineering Animals to Fight Major Insect-Born Diseases



WHO: Zika virus 'spreading explosively,' level of alarm 'extremely high'




Using Genetic Engineering to Fight Malaria



1.4 Million Deaths Per Year




Using Genetic Engineering to Fight Mosquito-Transmitted Diseases






Using Genetic Engineering to Fight Other Mosquito-Transmitted Diseases

Release of Insects Carrying a Dominant Lethal Allele



Releases of the genetically engineered Oxitec mosquito, commonly known as 'Friendly *Aedes aegypti*', reduced the dengue mosquito population in an area of Juazeiro, Brazil by 95%, well below the modelled threshold for epidemic disease transmission.







Field Tests of GM Mosquito Control Systems

Date	Location	Method	Outcome	Reference(s)
2005–2009	Italy	SIT	Release of irradiated male Aedes albopictus induced sterility in target populations; population suppression was observed in some locations	12
2009–2010	Cayman Islands	RIDL	Males of a RIDL strain of Aedes aegpit, OX513A, competed successfully for mates with wild mosquitoes; sustained release of these sterile males led to strong suppression of the target wild population	38, 39
2010	Malaysia	RIDL	RIDL OX513A males have life span and maximum dispersal similar to an unmodified comparator	47
2010	French Polynesia	пт	Sustained release of Aedes polymesiensis males infected with a Wolbacbia strain from Aedes riversi induced sterility in a target population	60
2011–Present	Brazil	RIDL	Sustained release of RIDL OX513A males led to strong suppression of two target wild populations; larger subsequent program in progress ^b	-
2011–Present	Australia	Invasive Wolbachia	Release of wMel-infected male and female Aedes aegypti led to the invasion and establishment of wMel Wolbachia in two target populations; releases in three additional areas are in progress ^c	41
2012–2013	Australia	Invasive Wolbachia	Release of wMelPop-infected male and female Aedes aegypti in two target areas; does not appear to have self-sustained ^c	-
2013–Present	Vietnam	Invasive Wolbachia	Release of wMelPop-infected male and female Aedes aegypti on an island; in progress ^c	-









	2014/2015 Before push for control	2015/2016 With various contro
Piracicaba *		
Cases of dengue	3,487	1,676
Population	386,449	386,449
Incidence	0.902%	0.437%
CECAP/Eldorado		
Cases of Dengue	133	12
Population	5,000	5,000
Incidence	2.66%	0.24%



FDA approves releasing GMO mosquitoes to fight Zika in Florida

The Florida Keys approve a trial release of genetically modified mosquitoes to combat Zika

Other tests have reduced mosquito populations by 90 percent

Guidance for Industry



Regulation of Mosquito-Related Products

II. BACKGROUND

Both FDA and EPA regulate products intended for use in or on animals. FDA is charged with protecting the public health by, among other things, ensuring that animal drugs are safe and effective [21 U.S.C. $\S 93(b)(2)(B)$]; under FIFRA, EPA is charged with protecting human health and the environment by ensuring registered pesticide products, when used according to the label directions, result in no unreasonable adverse effects to man or the environment. [7 U.S.C. $\S 136a(c)(5)$].

A. New Animal Drugs

The FD&C Act defines the term "drug" as, among other things, "articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals" and "articles (other than food) intended to affect the structure or any function of the body of man or other animals." [21 U.S.C. §321(g)(1)]. With very limited exceptions for animal drugs that are generally recognized as safe and effective or are subject to a "grandfather" clause, the FD&C Act defines drugs that are intended for use for animals as "new animal drugs." As such, these drugs are subject to applicable pre-market approval and/or other review requirements. [21 U.S.C. §321(v); 21 U.S.C. §360b; 21 U.S.C. §360ccc; 21 U.S.C. §360ccc-1].




TABLE 2-1 Systematic Risk Assessment and Management		
Step	Key questions	
Hazard identification	What event posing harmful consequences could occur?	
Risk analysis	How likely is the hazard?	
	What would be the harms from realization of the hazard, and how severe are they, taking into account social values?	
	What is the risk assessment as shown on a matrix of risk (likelihood of harm) plotted against severity of harm; see Figure 2-1, above)? Each cell of the matrix should be accompanied by a qualitative assessment of the response and a quantification of assurance needed to reduce harm if the cell's conditions were to occur.	
	How well established is the knowledge used to identify the hazard, estimate its risk, and predict harms?	
Risk reduction planning and implementation	What can be done (including bioconfinement and other confinement) to reduce risk, either by reducing the likelihood or mitigating the potential harms? Are there steps that can be taken to prepare for remediation?	
Risk tracking (monitoring)	How effective are the implemented measures for risk reduction?	
	Are they as good as, better than, or worse than planned?	
	What follow-up, corrective action, or intervention will be pursued if findings are unacceptable?	
	Did the intervention adequately resolve the concern?	
Remedial action	What remedial action should be taken?	
Transparency and public participation	How transparent should the entire process be? How much and what type of participation should there be in the steps above (and in risk characterization) by the public at large, by experts, and by interested and affected parties?	

How To Assess Risk?



Genetic Engineering is a **TECHNIQUE!**

- 1. Classical Breeding By Selective Mating (Thousands of Years)
- 2. Insertion of New Genes Into An Organism's Chromosomes (50 Years)
- 3. Editing Existing Genes Like A "Word Program" (1-2 Years)

Breeding or DNA Manipulation - They Are the SAME

Called Gene Manipulation WHAT IS A GMO???



Plants of Tomorrow

New Weapon to Fight Zika: The Mosquito

How mosquitoes with 'self-destruct' genes could save us from Zika virus

A Call to Fight Malaria One Mosquito at a Time by Altering DNA

Engineering Mosquitoes' Genes to Resist Malaria

Gene-Engineered Mosquitoes Can't Spread Malaria: Researchers


by MAGGIE FOX

Researchers in California say they have genetically engineered mosquitoes that cannot be infected with the malaria parasite — and they've done it in a way that virtually guarantees the trait will spread quickly in a population.


Highly efficient Cas9-mediated gene drive for population modification of the malaria vector mosquito *Anopheles stephensi* PNAS, November, 2015



Mosquito Genes Required For Harboring
Disease Parasites Are Targets For Genetic
Engineering & Disease Control



Mutate Genes & Prevent Pathogen From Residing in Mosquito






The CRISPR-Cas Bacterial Immunity System


CRISPR & Cas Discovered
In Yogurt Bacteria Resistant
To Viral Infections!

Clustered
Regular
Interspaced
Short
Palindromic
Repeats

CRISPR Associated System


Cas is an Endonuclease That Cleaves dsDNA





Plants of Tomorrow


The CRISPR-Cas Bacterial Immunity System is One of Many Bacterial Defense Systems That Prevent Phage Infection







The CRISPR-Cas Bacterial Immunity System


- 1. Phage Infects Bacteria
- 2. Spacer (Phage) DNA "Captured"
- 3. Spacer DNA Incorporated Into CRISPR Locus in Bacterial Genome
- 4. Spacer DNA Transcribed Into Guide RNA
- 5. Guide RNA Complexes With Cas Endonuclease Protein to Form Cleavage Complex
- 6. Cleavage Complex Recognizes Phage DNA With Complementary DNA Sequences in Subsequent Infection
- 7. Cas Endonuclease Digests Phage DNA and Infection Is Stopped








Target DNA








Advantages of Gene Editing Over "Cohen-Boyer" Genetic Engineering


- Simple Method to Edit, Correct, or Modify Any Endogenous Gene
- Multiple Genes Can Be Corrected at Once

Disadvantages of Gene Editing Over "Cohen-Boyer" Genetic Engineering

- Cannot Add Foreign Genes (e.g., GFP)
- Limited to Species-Specific Gene Corrections



How Can Gene Editing Be Used in Genetic Engineering?




- Editing Crop Gene Genomes (e.g., drought resistance)
- Editing Farm Animals (e.g., pathogen resistance)
- Eliminating Mosquito Borne Diseases
- Correcting Human Genetic Defects - Gene Therapy
- Human Trait Enhancement
- Editing Alters <u>Endogenous</u> Genes Because Specific Targets Are Needed!
- Foreign Genes Are Not Added to the Genome!

DNA Genetic Code of Life Entire Genetic Code of a Bacteria DNA Fingerprinting Cloning: Ethical Issues and Future Consequences

Plants of Tomorrow


Using Gene Editing to Eliminate Mosquito-Transmitted Diseases




Specific Mosquito Genes Are Required For the Plasmodium Life Cycle If Mutated, Mosquitos Cannot Harbor the Malaria Parasite!!




Editing Specific Mosquito Genes Using the CRISPR-Cas9 System Will Inhibit Infection With Plasmodium Parasites & Prevent Malaria!



Sequence Specific Changes in a Complex Genome!!!!



Genetic Engineering Mosquitos - "Gene Drive" Spreading Resistance to Plasmodium Throughout the Mosquito Population!




Mutate Plasmodium-Required Gene & Add Cas9-Guide RNA Into The Mosquito Genome Autocatalytic Gene Editing!!

Gantz et al., Science 348, 442 (2015); Hammond et al., Nat. Biotech. 34, 78 (2015)



Genetic Engineering Mosquitos - "Gene Drive" Spreading Resistance to Plasmodium Throughout the Mosquito Population!



NHERIT genetic change made to one parent usually has a oughly 50 percent chance of being passed down to


offspring.

But a novel technique called a gene drive system may be ble to increase the odds of spreading a genetic change to all offspring, and eventually through an entire popu-

Cut by Cas9

MATCH AND CUT A gene drive is a segment of engineered DNA that typically contains a guide sequence, a gene for an enzyme called Cas9 and any desired genes that researchers want to spread in the population.

If the guide sequence matches a stretch of DNA inherited from the wild parent, the wild DNA will be cut by the Cas9 enzyme.



REPAIR AND COPY The cell rushes to repair the

cut in the wild DNA, using the matching strand of DNA from the genetically modified with, a single copy from one parent as a template.

Once repaired, the wild DNA will contain both the Cas9 gene and the desired genes.



SPREAD

Because the gene drive effectively inserts itself into any wild DNA it is paired parent is enough to spread the gene drive and its desired genes to all


The technique has worked in the lab, but researchers are exploring the ethics and risks of releasing a gene drive into the wild.

Autocatalytic Gene Editing!

Gantz et al., Science 348, 442 (2015); Hammond et al., Nat. Biotech. 34, 78 (2015)




Potential Gene Drive Applications






Potential Gene Risks & Benefits



- Resistance
- Escape to Non-Target Organism
- Altering Ecological Balances
- Unforeseen
 Consequences in the
 Wild
- Eliminating Mosquito Borne Diseases & Saving Millions of Lives
- Reducing Ecological Impacts of Invasive Species
- Preventing Lyme
 Disease By Eliminating
 Animal Vectors



Recommendations For Using Gene Drive Systems

- More Research Needs To Be Performed Before Gene Drive Modified Organisms Are Released Into The Environment
- Phased Testing of Gene Drive Modified Organisms From Laboratory to the Field Should Be Carried Out Under the Relevant Regulatory Oversight
- Robust Ecological Assessment Needs to be Carried Out Before Each Gene Drive Test Should Be Approved
- Public Engagement Must Be Built Into the Risk Assessment, and Policies Should Be Developed For How Public Engagement Will Factor Into Research sand Policy Decisions
- Current Regulatory Framework For Assessing Risks and Potential Environmental Impacts of Releasing Gene Drive Modified Organisms Are Inadequate. Regulations Does Not Fit Within Purview of USDA, EPA, or FDA
- There Are Regulatory Concerns About Biosafety, Biosecurity, and Potential for Misuse For Harmful Purposes

Gene Drives on the Horizon - National Academy of Sciences - 2016




Other Uses Of CRISPR-Cas9 Editing






Using CRISPR-Cas9 Editing For Crop Improvement





Using CRISPR-Cas9 Editing For Correcting Human Genetic Disorders

Somatic Cell Gene Therapy




Germline Gene Therapy + Gene Enhancement



DNA Genetic Code of Life Entire Genetic Code of a Bacteria DNA Fingerprinting Cloning: Ethical Issues and Future Consequences

Plants of Tomorrow

Using CRISPR-Cas9 Editing For Correcting Sickle Cell Anemia





Recommendations For Using Human Gene Editing

International Summit on

- Basic & Preclinical Research on Human Gene Editing Should Proceed Subject To Appropriate Legal and Ethical Rules and Oversight
- Clinical Trials of Somatic Cell Gene Editing of Human Disease Genes Can Proceed Under Existing Gene Therapy Regulatory Frameworks
- Germline Editing of Human Genes Poses Many Important Issues (e.g., Difficulty of Predicting Harmful Effects, Permanent Change in Human Gene Pool, Permanent Genetic Enhancements Causing Social Inequalities, Changing Human Evolution), and it Would Be Irresponsible To Proceed Clinically Until These Issues Are Resolved
- Need For International Standards and Norms Governing the Clinical Uses of Human Genome Editing Because There is One Human Genome Shared By All of Humanity
- Genome Editing For Purposes Other Than Treatment For Prevention of Human Disease Should Not Be Carried Out

International Summit on Human Gene Editing, December, 2015 & Human Genome Editing Report, 2017, National Academy of Sciences

DNA Genetic Code of Life Entire Genetic Code of a Bacteria DNA Fingerprinting Cloning: Ethical Issues and Future Consequences Plants of Tomorrow

Removing Viral Sequences From Pig Genomes To Facilitate Human Pig Organ Transplants

